SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Aduro Biotech is a biotechnology business based in the US. Aduro Biotech shares (ADRO) are listed on the NASDAQ and all prices are listed in US Dollars. Aduro Biotech employs 69 staff and has a trailing 12-month revenue of around $28 million.
SoFi Invest
tastyworks
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $3.71 |
200-day moving average | $2.91 |
Wall St. target price | $18.75 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.15 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Aduro Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aduro Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aduro Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aduro Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Revenue TTM | $28 million |
---|---|
Gross profit TTM | $-48,610,000 |
Return on assets TTM | -13.9% |
Return on equity TTM | -87.44% |
Profit margin | -230.92% |
Book value | $2.88 |
Market capitalisation | $236.6 million |
TTM: trailing 12 months
We're not expecting Aduro Biotech to pay a dividend over the next 12 months.
Aduro Biotech's shares were split on a 1:5 basis on 2 October 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aduro Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Aduro Biotech shares which in turn could have impacted Aduro Biotech's share price.
Over the last 12 months, Aduro Biotech's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aduro Biotech's is 0.3861. This would suggest that Aduro Biotech's shares are less volatile than average (for this exchange).
Aduro Biotech, Inc. , an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B. V.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.